Pharmacists in Wales are to receive extra training in minor ailments as part of a scheme worth £100,000, the government has announced.
Public health chiefs have urged any eligible people to be vaccinated against measles after 231 confirmed cases were recorded in England in the first quarter of 2019.
The Competition and Markets Authority has provisionally found four drug companies to have broken competition law over the sale of an anti-nausea drug to the NHS.
All community pharmacies in Wales to have an independent prescriber as part of long-term plan for Welsh pharmacy
Every community pharmacy in Wales will employ an pharmacy independent prescriber by 2030 under the Welsh government’s long-term plan for the profession.
Emergency contraception services should be commissioned nationally as part of community pharmacy contract, CCA says
The Company Chemists’ Association has called on NHS England and other healthcare bodies to establish a single national pharmacy specification for emergency hormonal contraception services to be used by all healthcare commissioners in England.
Antiplatelet medicines, such as aspirin, appear to be safe and possibly beneficial for patients who have suffered an intracerebral haemorrhagic stroke, results from a clinical trial published in The Lancet suggest.
A European Medicines Agency committee has recommended that marketing authorisations for cough medicines containing fenspiride should be revoked, meaning they will no longer be marketed in the EU.
Two contraceptive pills will go out of stock until summer 2019, forcing prescribers to switch some women to alternative brands.
A deprescribing network led by two pharmacists will be launched in June 2019 to help address the issue of inappropriate polypharmacy across England and make deprescribing a “normal thing to do”.
Proposals for a five-year pharmacy apprenticeship will not go through to the next stage of development until representatives from the wider pharmacy industry are included in the trailblazer group, the Institute for Apprenticeships and Technical Education has announced.
The House of Commons has backed a motion calling on the government to ensure medical cannabis is made available to “appropriate patients”.
The Department of Health and Social Care has put forward plans to reduce its funding to Genomics England by £40m in 2019/2020 as the body receives a new funding model to match its latest target to sequence five million genomes in five years.
Half of hospital trusts in England are expected to be able to refer newly discharged patients to community pharmacy for help with taking their medicines by 2020.
Deaths from opioid overdose are “rising sharply” in England and Wales as part of a continuing global crisis, according to an analysis by the Organisation for Economic Co-operation and Development.
Gentamicin is no more effective overall than ceftriaxone as a first-line treatment for gonorrhoea but could be a useful alternative for some patients, researchers have said.
Oral contraceptive pills may be protective against anterior cruciate ligament tears in women, particularly in 15–19 year olds, a study has shown.
Researchers have used functional magnetic resonance imaging to show how cannabidiol counteracts some of the harmful effects of cannabis on the brain.
Non-steroidal anti-inflammatory drugs are unlikely to prevent Alzheimer’s disease in people at risk of developing the condition, study authors have concluded.
Over 60% of patients treated for a urinary tract infection lack evidence of the infection, a study carried out in a Birmingham emergency department has found.
Use of thiazide diuretics for three years or more may reduce the risk of low-energy fracture in people with Alzheimer’s disease, study results have suggested.
Women exposed to antibiotics in middle or older adulthood have an increased risk of developing cardiovascular disease, a study published in the European Heart Journal suggests.
Patients with cancer who use medical cannabis to treat symptoms, such as pain and neuropathy, tend to favour formulations with a higher ratio of the psychoactive component, tetrahydrocannabinol, compared with non-cancer patients.